Skip to content
GLP-1 Savers
Menu

Evidence review

Compounded vs Brand-Name GLP-1: Which Actually Saves You Money

Cash-pay compounded GLP-1 runs $65-$349/mo; brand-name Wegovy and Zepbound list near $1,000+. Here's when each one is actually the cheaper choice.

By The Savers Desk, Deals & Pricing Editor

The honest answer to "which is cheaper" is: it depends entirely on your insurance. Brand-name and compounded GLP-1s often contain the same active molecule — semaglutide or tirzepatide — but they reach you through completely different price channels. Get the channel right and you can pay a fraction of what your neighbor pays for the same result.

The two price worlds

Brand-name Wegovy and Zepbound are FDA-approved finished drugs12 with published U.S. list prices north of $1,000 a month before any coupon or coverage. Compounded semaglutide and tirzepatide come from licensed compounding pharmacies and, across the cash-pay telehealth programs we track, run roughly $65 to $349 a month per each provider's published pricing (last reviewed 2026). That is not a rounding difference — it's an order of magnitude.

When brand-name is actually the cheaper path

If you have commercial insurance that covers Wegovy or Zepbound, or you qualify for the manufacturer savings cards, brand-name can drop to a low copay that beats any cash compounded price. In that case, paying cash for compounded would be overpaying. Check your formulary and the manufacturer savings program first — a covered brand prescription is often the single cheapest route when coverage exists.

When compounded wins on price

For the large group paying cash — no coverage, a high deductible, or a plan that excludes anti-obesity drugs — compounded is usually far cheaper. A flat $99-$149 compounded semaglutide undercuts an uncovered $1,000+ brand sticker so decisively that the comparison isn't close. This is the scenario most of our provider reviews are built for: cash-pay shoppers who want the molecule without the brand markup.

The catch: compounded isn't the same regulatory product

Cheaper comes with a trade-off worth naming. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality the way brand-name drugs are3. That doesn't make them illegitimate — it makes pharmacy verification the price of admission. Favor programs naming a LegitScript-certified or state-licensed pharmacy, and read is cheap compounded GLP-1 safe? how to vet a low price before you buy on sticker alone.

Don't compare the intro rate

When you run the compounded-vs-brand math, use the compounded program's ongoing flat price, not a first-month teaser. A $99 intro that resets to $299 changes the whole calculation. We explain the pattern in how to spot a GLP-1 teaser-rate trap — it's the easiest way to think you're saving while quietly overpaying.

The bottom line

Covered by insurance? Price the brand first — it may be your cheapest month. Paying cash? Compounded almost always wins, provided you verify the pharmacy and use the true flat rate. To put real numbers side by side, start with our Value Score reviews and compare tools, which price every program against a brand-name cash reference so the savings are auditable.

Frequently asked questions

Is compounded GLP-1 the same as brand-name Wegovy or Zepbound?

It often contains the same active molecule, but compounded drugs are not FDA-approved and aren't reviewed for safety, effectiveness, or quality the way brand-name drugs are. The molecule may match; the regulatory status does not.

Is brand-name ever cheaper than compounded?

Yes. If your insurance covers Wegovy or Zepbound, or you qualify for manufacturer savings cards, the covered copay can beat any cash compounded price. Always check your formulary before assuming compounded is cheaper.

How much does cash-pay compounded GLP-1 cost?

Across the cash-pay programs we track it runs roughly $65 to $349 a month depending on the provider, molecule, and state, per each provider's published pricing.

References

  1. U.S. Food and Drug Administration (2021). FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 (Wegovy). FDA.gov. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
  2. U.S. Food and Drug Administration (2023). FDA Approves New Medication for Chronic Weight Management (Zepbound). FDA.gov. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  3. U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Continue reading